Strain Data Sheet
RBRC00306
Strain Information | |
|---|---|
| Image |  |
| BRC No. | RBRC00306 |
| Type | Targeted Mutation |
| Species | Mus musculus |
| Strain name | B6.129S1-Tnf<tm1Ljo>/Rbrc |
| Former Common name | TNF.K.O |
| H-2 Haplotype | |
| ES Cell line | W9.5 [129S1/Sv-Oca2<+> Tyr<+> Kitl<+>] |
| Background strain | C57BL/6JJcl |
| Appearance | black [a/a B/B C/C] |
| Strain development | Developed by Drs. Michael W Marion and Lloyd J. Old, Ludwig Institute for Cancer Research in 1999. Neomycin cassettes were inserted into the nucleotides 3704-5364 of the Tnf gene. |
| Strain description | B6.129S1-Tnf<tm1Ljo>/Rbrc. TNF, tumor necrosis factor is a multifunction proinflammatory cytokine, play a critical role in regulating of the development and function of the immune system. Homozygous mutant mice show no cytotoxicity of TNF. |
| Colony maintenance | Homozygote x HomozygoteHomozygous mutant mice show a normal development and no gross morphological abnormalities. |
| References | Proc. Natl. Acad. Sci. USA, 94, 8093-8098 (1997). 9223320 |
Health Report | |
|---|---|
| Examination Date / Room / Rack | |
Gene | |
|---|---|
| Gene info | Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter Tnftumor necrosis factor17Tnf<tm1Ljo>targeted mutation 1, Lioyd J Oldtumor necrosis factor alpha, DIF, Tnfa, TNFSF2, TNFalpha, TNF-alpha, TNF alpha, Tnfsf1a, tumor necrosis factor-alpha Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter neoneomycin resistance gene (E. coli)17neo; neomycin;mouse phosphoglycerate kinase promoter (PGK promoter) |
Ordering Information | |
|---|---|
| Donor DNA | mouse tumor necrosis factor genomic DNA, E. coli neo, mouse phosphoglycerate kinase promoter (PGK promoter) |
| Research application | Developmental Biology Research Immunology and Inflammation Research covid19_onset |
| Specific Term and Conditions | The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. Inquiries regarding the use of the BIOLOGICAL RESOURCE for commercial purposes including research use by for-profit companies should be directed to: Dr. Par Olsson Director, Intellectual Property Ludwig Institute for Cancer Research 666 Third Avenue New York, NY 10017 Tel. +1-212-450-1500 Fax. +1-212-450-1535 Ownership of modifications and derivatives including crossed progeny of the BIOLOGICAL RESOURCE will be determined in accordance with applicable law governing inventorship and the creative input of the parties and the Recipient agrees to report any such progeny to LICR. The RIKEN BRC, the LICR and Recipient agree that no party will license or otherwise commercialize any such invention in the absence of an agreement to be negotiated in good faith by the parties hereto, providing for, inter alia, the sharing of royalty income. |
| Depositor | Gerd Ritter (Ludwig Institute for Cancer Research) |
| Strain Status |  Frozen sperm |
| Strain Availability | Recovered litters from cryopreserved sperm (2 to 4 months) Cryopreserved sperm (within 1 month) |
| Additional Info. | Necessary documents for ordering:
Genotyping protocol -PCR- |
BRC mice in Publications |
|---|
| No Data |